Ventyx Biosciences (VTYX) Competitors $2.40 +0.02 (+0.63%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. KALV, MNMD, TYRA, ORGO, BCAX, RAPP, MAZE, RZLT, RLAY, and IMTXShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include KalVista Pharmaceuticals (KALV), Mind Medicine (MindMed) (MNMD), Tyra Biosciences (TYRA), Organogenesis (ORGO), Bicara Therapeutics (BCAX), Rapport Therapeutics (RAPP), Maze Therapeutics (MAZE), Rezolute (RZLT), Relay Therapeutics (RLAY), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors KalVista Pharmaceuticals Mind Medicine (MindMed) Tyra Biosciences Organogenesis Bicara Therapeutics Rapport Therapeutics Maze Therapeutics Rezolute Relay Therapeutics Immatics Ventyx Biosciences (NASDAQ:VTYX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Is VTYX or KALV more profitable? Ventyx Biosciences' return on equity of -48.89% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -48.89% -44.87% KalVista Pharmaceuticals N/A -134.07%-82.65% Do institutionals & insiders hold more shares of VTYX or KALV? 97.9% of Ventyx Biosciences shares are held by institutional investors. 18.2% of Ventyx Biosciences shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility and risk, VTYX or KALV? Ventyx Biosciences has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Do analysts rate VTYX or KALV? Ventyx Biosciences presently has a consensus price target of $7.50, suggesting a potential upside of 213.15%. KalVista Pharmaceuticals has a consensus price target of $26.29, suggesting a potential upside of 68.91%. Given Ventyx Biosciences' higher probable upside, equities research analysts clearly believe Ventyx Biosciences is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has better valuation & earnings, VTYX or KALV? KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$135.12M-$1.68-1.43KalVista PharmaceuticalsN/AN/A-$183.44M-$3.69-4.22 Does the media prefer VTYX or KALV? In the previous week, KalVista Pharmaceuticals had 8 more articles in the media than Ventyx Biosciences. MarketBeat recorded 12 mentions for KalVista Pharmaceuticals and 4 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 1.69 beat KalVista Pharmaceuticals' score of 0.97 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive KalVista Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVentyx Biosciences beats KalVista Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.79M$3.17B$5.83B$9.99BDividend YieldN/A2.27%6.70%4.54%P/E Ratio-1.4321.4775.7126.27Price / SalesN/A249.28454.4283.26Price / CashN/A44.1225.7029.14Price / Book0.6710.0211.476.34Net Income-$135.12M-$53.33M$3.28B$270.02M7 Day Performance-2.64%2.01%1.24%2.59%1 Month Performance-14.77%11.69%11.12%9.01%1 Year Performance9.36%13.74%59.46%26.34% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.7296 of 5 stars$2.40+0.6%$7.50+213.2%+9.7%$170.79MN/A-1.4330News CoverageKALVKalVista Pharmaceuticals4.1051 of 5 stars$13.46-0.4%$26.29+95.3%+29.3%$677.57MN/A-3.65100Upcoming EarningsMNMDMind Medicine (MindMed)2.355 of 5 stars$8.88-9.2%$24.71+178.3%+57.9%$675.66MN/A-5.8040TYRATyra Biosciences2.727 of 5 stars$12.67+2.4%$30.83+143.4%-41.1%$675.28MN/A-7.1220Positive NewsORGOOrganogenesis3.9326 of 5 stars$5.15+0.6%$7.50+45.6%+93.1%$653.32M$482.04M-36.78950Positive NewsBCAXBicara TherapeuticsN/A$11.94+0.3%$32.25+170.1%N/A$651.48MN/A-3.7732Positive NewsRAPPRapport Therapeutics1.5758 of 5 stars$17.63+4.9%$29.50+67.3%+54.8%$643.46MN/A-7.05N/ATrending NewsAnalyst ForecastOptions VolumeMAZEMaze TherapeuticsN/A$14.49+1.5%$25.60+76.7%N/A$635.40M$167.50M0.00121Positive NewsRZLTRezolute3.0344 of 5 stars$7.12-1.4%$12.50+75.6%+82.8%$619.41MN/A-6.1940RLAYRelay Therapeutics2.77 of 5 stars$3.59-2.7%$17.08+375.9%-34.9%$618.96M$10.01M-1.84330News CoverageIMTXImmatics2.117 of 5 stars$5.09-3.6%$14.67+188.1%-50.5%$618.69M$168.65M-7.83260Positive NewsHigh Trading Volume Related Companies and Tools Related Companies KalVista Pharmaceuticals Competitors Mind Medicine (MindMed) Competitors Tyra Biosciences Competitors Organogenesis Competitors Bicara Therapeutics Competitors Rapport Therapeutics Competitors Maze Therapeutics Competitors Rezolute Competitors Relay Therapeutics Competitors Immatics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
